BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/16/2022 1:07:50 PM | Browse: 445 | Download: 640
 |
Received |
|
2021-12-29 03:11 |
|
Peer-Review Started |
|
2021-12-29 03:12 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-03-10 05:38 |
|
Revised |
|
2022-03-25 03:06 |
|
Second Decision |
|
2022-04-29 03:12 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-04-30 07:34 |
|
Articles in Press |
|
2022-04-30 07:34 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-05-25 08:38 |
|
Publish the Manuscript Online |
|
2022-06-16 13:07 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Tarik Silk, Mikhail Silk and Jennifer Wu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jennifer Wu, MD, Associate Professor, Attending Doctor, Division of Hematology and Oncology, Perlmutter Cancer Center of NYU Langone Health, NYU School of Medicine, 462 First Ave, BCD556, New York, NY 10016, United States. jennifer.wu@nyulangone.org |
| Key Words |
Chemoembolization; Hepatocellular carcinoma; Immunotherapy; Drug combinations; Review; Medical oncology |
| Core Tip |
Barcelona clinic liver cancer intermediate stage disease that exceeds “the up to seven” criteria, especially with lesions larger than 5 cm, is less likely to respond to transarterial chemoembolization (TACE) alone and is therefore a disease that may respond better to systemic therapy. The use of “the up to seven” criteria can be a helpful guidepost for when to consider systemic therapy alone or in addition to TACE. With the recent breakthroughs in immunotherapy for advanced hepatocellular carcinoma which clearly demonstrated overall survival advantage over single agent tyrosine kinase inhibitors sorafenib, it is promising that the use of immunotherapy would likely lead to better outcome when used in intermediate disease. |
| Publish Date |
2022-06-16 13:07 |
| Citation |
Silk T, Silk M, Wu J. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. World J Gastroenterol 2022; 28(23):2561-2568 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i23/2561.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i23.2561 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
